3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Hematologic Neoplasms
1
Cholangiocarcinoma
1
Camurati-Engelmann Syndrome
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
23
Cisplatin
16
pembrolizumab
6
Fluorouracil
6
pemigatinib
4
Radiotherapy
3
Oxaliplatin
3
Leucovorin
3
Drug Therapy
3
infigratinib
2
durvalumab
2
ceritinib
2
aldesleukin
2
Radiosurgery
2
Photochemotherapy
2
Nivolumab
2
Liver Transplantation
2
Dexamethasone
2
Cholangiopancreatography, Endoscopic Retrograde
2
Carboplatin
2
Capecitabine
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
spartalizumab
1
seribantumab
1
perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane)
1
peginterferon alfa-2b
1
pazopanib
1
padeliporfin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Cholangiocarcinoma
×
bintrafusp alfa protein, human
×
Clear all
NCT04727541
2022-05-23
NEOBIL
AIO-Studien-gGmbH
Phase 2
Terminated
3 enrolled